Cooperative Agreement U24CA114793

This $8.58 million cooperative agreement from the Department of Defense's Uniformed Services University Medical Research Projects program (CFDA 12.750) supports the Gynecologic Cancer Center of Excellence (GYN-COE) Core from April 2021 through April 2023. The GYN-COE aims to identify molecular alterations in gynecologic cancers and develop novel strategies for prevention, early detection, and precision treatment through investigating carcinogenesis and drug resistance in pre-clinical and...

The Department of the Army Medical Command awarded a $2,843,750 Project Grant to The Trustees of the University of Pennsylvania under the Military Medical Research and Development program (CFDA 12.420). The grant supports the Department of Defense Omics Consortium to Study the Origins of Ovarian Cancer (DOCSOOC) from August 15, 2022 to August 14, 2026. The Consortium will develop a pathology resource for pan-omic studies of tubal precursors to ovarian cancer. It will facilitate communication and...

This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...

Federal Grant Award Summary The National Cancer Institute awarded Oraliva, Inc. a $400,000 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 1, 2025, through August 31, 2026, to develop a novel point-of-care (POC) diagnostic tool for gynecological screening in low-resource settings. Oraliva will leverage its artificial intelligence-linked cytomics-on-a-chip (ONC-INCYT) technology to create the first rapid, integrated human papillomavirus...

The National Cancer Institute awarded Massachusetts General Hospital (MGH) a Project Grant totaling $744,575 under the Cancer Cause and Prevention Research program (CFDA 93.393) on May 16, 2025, with performance through April 30, 2030. The grant supports research to define the genomic and biologic impact of LINE-1 (Long Interspersed Element-1) activity in fallopian tube epithelial cells and its contribution to high-grade serous ovarian cancer (HGSOC) pathogenesis. The research will investigate...

Federal Cooperative Agreement Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $225,511 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 16, 2026, with a completion date of February 29, 2028. The award supports the development and validation of a plasma-based multimodal digital polymerase chain reaction (PCR) assay to detect androgen receptor (AR) somatic...

Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $660,079 Cooperative Agreement to the University of California Santa Cruz, effective September 1, 2025 through August 31, 2030, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds the maintenance and expansion of BRCA Exchange, a comprehensive knowledgebase that aggregates and annotates variants in BRCA1 and BRCA2 genes to support clinical cancer genetics. BRCA Exchange serves as...

The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...

Federal Cooperative Agreement Award Summary The Beckman Research Institute of the City of Hope received a $738,675 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop an innovative exosome-based liquid biopsy assay for the non-invasive early detection of colorectal adenomas and cancers. Awarded on March 16, 2026, with a completion date of February 28, 2031, this five-year project addresses a critical...

Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $399,829 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel research models for investigating sex-based disparities in glioblastoma (GBM). The award, effective July 7, 2025 through June 30, 2027, funds the creation of investigative tools and methodologies to examine how sex chromosomes and sex hormones influence GBM phenotype, proliferation, and...